In this issue:
Benefit of daratumumab addition to standard treatment in NDMM
DARA-POM-D combination therapy in RRMM patients
Pvd triplet therapy for patients with RRMM previously treated with lenalidomide
Carfilzomib vs bortezomib with melphalan-prednisone for transplant ineligible NDMM patients
Efficacy of first-line treatments for MM patients not eligible for transplantation
Impact of prior diagnosis of MG on outcomes in NDMM
Management of infectious complications in MM patients
Tandem autologous-allogeneic hematopoietic cell transplantation for MM
CAR T-Cell therapy bb2121 in RRMM
Postoperative radiotherapy for MM of long bones
Please login below to download this issue (PDF)